David Parkinson

David R.
Parkinson is the founder of Refuge Biotechnologies, Inc. Currently, Dr. Parkinson serves as Director at Angiocrine Bioscience, Inc. and Director at The Multiple Myeloma Research Foundation, Inc. Formerly, Dr. Parkinson was President, Chief Executive Officer & Director at ESSA Pharma, Inc. from 2016 to 2025, President, Chief Executive Officer & Director at Nodality, Inc. from 2007 to 2012, Chairman-Clinical Advisory Board at Zyngenia, Inc. from 2012 to 2014, Independent Director at Ambit Biosciences Corp.
from 2013 to 2014, Independent Non-Executive Director at 3SBio, Inc. from 2014 to 2021, Independent Director at Tocagen, Inc. from 2015 to 2020, Director at Abbott Biotherapeutics Corp.
from 2008 to 2010, Associate Director-Cancer Therapy Medicine at National Cancer Institute in 1997, Director at American Association for Cancer Research from 2006 to 2009, Director at Pierian Biosciences LLC from 2016 to 2018, VP-Oncology Development & Commercialization at Amgen, Inc. from 2003 to 2006, Senior VP-Oncology Research & Development at Biogen, Inc. in 2007, and VP-Global Clinical Oncology Development at Novartis Corp.
in 2003.
Other former roles include Chairman at US Food & Drug Administration, Independent Director at Threshold Pharmaceuticals, Inc., Director at Cerulean Pharma, Inc., Director at Multiple Myeloma Research Consortium, Director at Ontario Institute for Cancer Research, Director at Realm Therapeutics Plc, Independent Director at CTI BioPharma Corp., Vice President-Global Clinical Oncology at Novartis International AG, Venture Partner at NEA Management Co. LLC, Principal at The University of Texas at Austin, Principal at Tufts University, Principal at The University of Texas M.D.
Anderson Cancer Center, President at International Society for Biological Therapy of Cancer, and Partner at New Enterprise Associates (India) LLC.
Education includes a doctorate degree conferred in 1977 from the University of Toronto Faculty of Medicine.